REG - Futura Medical PLC - Director/PDMR Shareholding

Futura MedicalAnnouncement

22/04/2020 15:15

RNS Number : 5459K
  
Futura Medical PLC
  
22 April 2020
  
 

22 April 2020
Futura Medical plc
Director Shareholding
Futura Medical Plc (AIM: FUM) ("Futura" or "the Company") today received notification that on 22 April 2020, James Barder, the Company's CEO, sold 173,000 ordinary shares of 0.2 pence in the Company ("Ordinary Shares") at a price of 11.50 pence per share and repurchased 173,000 Ordinary Shares at a price of 11.52 pence per share.  These trades were carried out as part of a "Bed and ISA" process, allowing James to move his existing shareholding into an ISA.
Following these trades James Barder's beneficial holding remains unchanged at 1,093,472 ordinary shares with an aggregate beneficial and non-beneficial holding of 1,210,972 Ordinary Shares, representing 0.49 per cent. of the current total voting rights of the Company. James Barder also has options over 1,750,000 Ordinary Shares.
Further details are contained within the notification below, made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014.
For further information please contact:
Futura Medical plc 

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:

Liberum

Bidhi Bhoma/ Euan Brown/ Kane Collings

Tel: +44 (0) 20 3100 2000
 
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
 
Notes to editors:
 
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk. 
MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED.  MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
 



1 
 


Details of the person discharging managerial responsibilities / person closely associated 
 




a) 
 


Name 
 
 


James Barder
 




2 
 


Reason for the notification 
 




a) 
 


Position/status 
 
 


CEO




b) 
 


Initial notification /Amendment 
 
 


Initial




3 
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
 




a) 
 


Name 
 
 


Futura Medical Plc




b) 
 


LEI 
 
 


21380053QLT46UNV2303




4 
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
 
 




a) 
 


Description of the financial instrument, type of instrument 


Ordinary Shares of 0.2 pence














Identification code 


ISIN: GB0033278473














b) 
 


Nature of the transaction 
 
 


Transfer of 173,000 Ordinary Shares, via sale and repurchase




c) 
 


Price(s) and volume(s) 




























Price(s)


Volume(s)
















11.50p


173,000 (sale)
















11.52p


173,000 (purchase)






























d) 
 


Aggregated information 


















- Aggregated volume
- Price
- Total
 
- Aggregated volume
- Price
- Total
 


173,000 (sale)
11.50p
£19,895.00
 
173,000 (purchase)
11.52p
£19,929.60




e) 
 


Date of the transaction 
 
 


22 April 2020




f) 
 


Place of the transaction 
 
 


London Stock Exchange, AIM Market (XLON)



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
DSHFLFLSSIIFFII